Abstract 905MO
Background
Clinical unmet needs still abound for an accurate noninvasive test to facilitate early detection of lung cancer. Here, we describe a novel combination of clinical, imaging and DNA methylation biomarkers to improve the classification of pulmonary nodules.
Methods
We conducted a prospective collection and retrospective blinded evaluation trial comprising 1,380 subjects in 24 sites. We developed a 10-feature combined clinical and imaging biomarkers model (CIBM) for the classification of malignant and benign pulmonary nodules in a cohort (n=839) and validated it in 2 cohorts (n1=258, n2=283). Then we integrated CIBM model with our previously established ctDNA methylation model (PulmoSeek) to create a new combined model (n=258), PulmoSeek Plus, and verified it independently (n=283). Meanwhile, a 12-feature imaging biomarker model for invasiveness differentiation (IBMI) of lung adenocarcinoma were established (n=624) and validated (n1=202, n2=193). Clinical utility of the models was evaluated using a decision curve analysis.
Results
The CIBM model achieved improved AUCs (0.85 [95% CI 0.80-0.89]; 0.85 [0.81-0.89]) over Mayo model (0.60 [0.52-0.68]; 0.57 [0.50-0.64]) and Brock model (0.70 [0.63-0.77]; 0.67 [0.60-0.73]) in the two validation cohorts, respectively. PulmoSeek Plus had AUC of 0.90 [0.88-0.93] in the combined set (n=541), significantly outperforming both CIBM (0.85 [0.82-0.88]) and PulmoSeek (0.85 [0.82-0.88]). The overall sensitivity was 98.0% [0.97-1.00] at a fixed specificity of 50.0% for rule out. High sensitivity of 98.0% [0.96-0.99] was maintained in early-stage lung cancer (0-I, n=390) and 99.2% [0.96-1.00] in 5-10 mm nodules (n=123). The IBMI model had AUCs of 0.87 [0.82-0.92], 0.89 [0.84-0.93] and 0.89 [0.85-0.92] in the two validation sets and the combined set. At a risk score of 0.54, PulmoSeek Plus improved net benefit by 60.8%, equivalent to detecting additional 82.4% of lung cancers. Using two cut-offs of PulmoSeek Plus scores to reclassify would have reduced 46.0% unnecessary surgeries and reduced 73.2% delayed treatment.
Conclusions
PulmoSeek Plus model improves the early detection and classification of pulmonary nodules, potentially worth using in clinical decision-making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Anchordx Medical Co., Ltd., Guangzhou, China.
Funding
Anchordx Medical Co., Ltd., Guangzhou, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
LBA72 - Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
Presenter: Maria Fernanda Mosele
Session: Mini Oral session: Basic science & translational research
Resources:
Abstract
Slides
Webcast
904MO - Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Mini Oral session: Basic science & translational research
Resources:
Abstract
Slides
Webcast
68MO - Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies
Presenter: Miriam Hägele
Session: Mini Oral session: Basic science & translational research
Resources:
Abstract
Slides
Webcast
1661MO - Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma
Presenter: François-Xavier DANLOS
Session: Mini Oral session: Basic science & translational research
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA72, 904MO, 68MO and 1661MO
Presenter: Marleen Kok
Session: Mini Oral session: Basic science & translational research
Resources:
Slides
Webcast
1662MO - Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)
Presenter: Rebecca Simpson
Session: Mini Oral session: Basic science & translational research
Resources:
Abstract
Slides
Webcast
1663MO - DAV132 prevents antibiotic-induced intestinal microbiota dysbiosis and maintains anti-PD-1 efficacy: A proof-of-concept in tumor-bearing mice transplanted with human feces
Presenter: Meriem Messaoudene
Session: Mini Oral session: Basic science & translational research
Resources:
Abstract
Slides
Webcast
Invited Discussant 1662MO and 1663MO
Presenter: John Stagg
Session: Mini Oral session: Basic science & translational research
Resources:
Slides
Webcast
1664MO - Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients
Presenter: Eric Zhao
Session: Mini Oral session: Basic science & translational research
Resources:
Abstract
Slides
Webcast
69MO - 5-Hydroxymethycytosine analysis reveals stable epigenetic changes in tumor tissue that enable cfDNA cancer predictions
Presenter: Felix Feng
Session: Mini Oral session: Basic science & translational research
Resources:
Abstract
Slides
Webcast